ClinicalTrials.gg
CompletedNCT07943975Updated Nov 17, 2026

Thoracic Epidural Analgesia Versus Erector Spinae Plane Block After Median Sternotomy

An interventional study of Thoracic Epidural Analgesia (TEA) and Bilateral erector spinae plane block in Pain, Postoperative, Cardiac Surgical Procedures and Sternotomy, sponsored by Karadeniz Technical University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Karadeniz Technical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Nov 2023, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Pain, Postoperative with a site in Turkey — 264 open to participants now, 297 under way, none of them phase 3. Pain, Postoperative · Turkey.

Enrollment
171st of 884
99 · median 70
Started
2023
with 132 others
No phase
815 of 1,099
217 open now
Registered
1,097th of 1,099
by date

Among the 1,099 studies in Pain, Postoperative with a site in Turkey, this one is the 171st largest by enrollment of the 884 interventional ones that give a count, is one of 133 that started in 2023, is one of 815 with no phase, and was the 1,097th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

264 of the 1,099 studies in Pain, Postoperative with a site in Turkey are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Pain, Postoperative with a site in Turkey, or all of them as a file.
02

Study summary

Pain after open-heart surgery performed through a median sternotomy can make it difficult for patients to breathe deeply and cough, which may lead to breathing problems after surgery. The goal of this clinical trial is to compare three methods of pain control in adults having open-heart surgery: thoracic epidural analgesia, bilateral erector spinae plane block, and intravenous analgesia alone.

The main questions it aims to answer are:

  • Do thoracic epidural analgesia and erector spinae plane block lower pain scores at rest during the first 48 hours after removal of the breathing tube, compared with intravenous analgesia?
  • Do these techniques improve breathing function and recovery after surgery?

Participants were randomly assigned to one of three groups. Before general anesthesia, one group received a thoracic epidural catheter with a continuous infusion of local anesthetic for 48 hours, one group received a single ultrasound-guided erector spinae plane block on both sides of the back, and one group received no regional block. All participants received the same intravenous pain medication after surgery, with additional medication if their pain score was above 4 out of 10. Pain scores, breathing exercise volumes, breathing-related complications, and length of stay were recorded.

Read the detailed description

This is a single-center, prospective, randomized, parallel-group, three-arm controlled trial conducted at Karadeniz Technical University Faculty of Medicine.

Randomization and masking: Participants were allocated in a 1:1:1 ratio using a computer-generated random number table prepared by an investigator not involved in enrollment, interventions, or outcome assessment. Allocation was concealed in sequentially numbered, sealed, opaque envelopes opened in the operating room immediately before the procedure. Postoperative outcomes were recorded by an assessor blinded to group allocation. No sham procedure was used; participants and the anesthesiologists performing the interventions were not blinded.

Anesthesia: All participants received standard monitoring and intravenous sedation before the intervention. General anesthesia was induced with thiopental, fentanyl, and vecuronium and maintained with sevoflurane titrated to a bispectral index of 40-60. All participants were transferred to the intensive care unit after surgery.

Postoperative analgesia: All participants received intravenous paracetamol 1 g every 8 hours. Participants with a Numerical Rating Scale score above 4 received intravenous tramadol 50 mg as rescue analgesia, followed by diclofenac 75 mg if needed.

Respiratory management: Participants were extubated according to predefined criteria and then performed breathing exercises with a flow-oriented incentive spirometer. Supplemental oxygen was increased, and noninvasive ventilation or reintubation was used, according to a predefined stepwise protocol.

Sample size: Based on previously published pain scores, 30 participants per group were required; 33 per group were enrolled to allow for dropouts.

03

Conditions studied

  • Pain, Postoperative
  • Cardiac Surgical Procedures
  • Sternotomy

Browse trials for

Keywords

  • Erector spinae plane block
  • Thoracic epidural analgesia
  • Median sternotomy
  • Open-heart surgery
  • Regional anesthesia
  • Incentive spirometry
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years
  • (ASA) physical status II-IV
  • below 35 kg/m2
  • Scheduled for elective open-heart surgery via median sternotomy
  • Written

Exclusion criteria

Exclusion Criteria:

  • Regular use of analgesics, antidepressants, anticonvulsants, or
  • Psychiatric disorder
  • below 40%
  • Allergy to any study drug
  • History of alcohol or drug abuse
  • Coagulopathy
  • Preoperative anticoagulant or antiplatelet therapy
  • Emergency surgery
  • Infection at the puncture site
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
99 participants (actual)

Study arms

  • Active comparator
    Thoracic Epidural Analgesia (TEA)

    A thoracic epidural catheter was placed at the T4-T5 or T5-T6 interspace before induction of general anesthesia. Participants received an epidural bolus followed by a continuous epidural infusion of bupivacaine until 48 hours after surgery. No intraoperative opioid was given other than the induction dose of fentanyl.

    Procedure: Thoracic Epidural Analgesia (TEA)

  • Experimental
    Erector Spinae Plane Block (ESP)

    A single-shot, ultrasound-guided bilateral erector spinae plane block was performed at the T4 or T5 level before induction of general anesthesia. No intraoperative opioid was given other than the induction dose of fentanyl.

    Procedure: Bilateral erector spinae plane block

  • Active comparator
    Intravenous Analgesia (Control)

    No regional technique was performed. Participants received an intraoperative intravenous fentanyl infusion from tracheal intubation until the end of surgery.

    Other: Intravenous analgesia

Interventions

  • ProcedureThoracic Epidural Analgesia (TEA)

    Epidural space identified at T4-T5 or T5-T6 with an 18-gauge Tuohy needle using loss of resistance to saline, followed by catheter insertion. After a test dose of 3 ml of 2% lidocaine with epinephrine, 25-30 mg of bupivacaine diluted in 10 ml of saline was injected. After tracheal intubation, 0.3% bupivacaine was infused at 3 ml/h until 48 hours after surgery. At least 2 hours elapsed between catheter insertion and systemic heparinization.

  • ProcedureBilateral erector spinae plane block

    With a high-frequency linear ultrasound transducer placed 3 cm lateral to the spinous process at T4 or T5, a 22-gauge, 80-mm block needle was advanced in-plane to the transverse process. After confirmation by hydrodissection with 2-3 ml of saline, 20 ml of 0.375% bupivacaine was injected on each side (40 ml, 150 mg in total).

  • OtherIntravenous analgesia

    Intraoperative intravenous fentanyl infusion at 0.5-1 mcg/kg/h from tracheal intubation until the end of surgery, without any regional technique.

06

What researchers measure

Primary outcomes

  1. Pain intensity at rest

    Pain at rest assessed with the 11-point Numerical Rating Scale (NRS), where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain.

    Time frame: 0, 2, 6, 12, 24, 36, and 48 hours after extubation

Secondary outcomes

  1. Proportion of participants requiring rescue analgesia

    Number of participants who received intravenous tramadol 50 mg for an NRS score above 4.

    Time frame: up to 48 hours after extubation

  2. Total tramadol consumption

    Cumulative dose of rescue tramadol in milligrams.

    Time frame: Up to 48 hours after extubation

  3. Incentive spirometry volume

    Inspiratory volume in milliliters estimated with a flow-oriented incentive spirometer (indicated flow multiplied by the time the ball remained elevated), recorded as the mean of the three best consecutive breaths with the participant sitting upright.

    Time frame: 0, 2, 6, 12, 24, 36, and 48 hours after extubation

  4. Incidence of tachypnea

    Number of participants with a respiratory rate above 20 breaths per minute.

    Time frame: Up to 48 hours after extubation

  5. Need for higher-flow supplemental oxygen

    Number of participants requiring face-mask oxygen at 4-8 l/min because of tachypnea or peripheral oxygen saturation below 90%.

    Time frame: Up to 48 hours after extubation

  6. Need for noninvasive mechanical ventilation or reintubation

    Number of participants requiring noninvasive mechanical ventilation or tracheal reintubation.

    Time frame: Up to 48 hours after extubation

  7. Time to extubation

    Time in hours from the end of surgery to tracheal extubation.

    Time frame: From the end of surgery until extubation, assessed up to 48 hours

  8. Time to first mobilization

    Time in hours from the end of surgery to first mobilization.

    Time frame: From the end of surgery until first mobilization, assessed up to 7 days

  9. Length of intensive care unit stay

    Number of days from intensive care unit admission to discharge from the unit.

    Time frame: From intensive care unit admission until unit discharge, assessed up to 30 days

  10. Length of hospital stay

    Number of days from surgery to hospital discharge.

    Time frame: From surgery until hospital discharge, assessed up to 30 days

07

Study locations

1 site
  • Karadeniz Technical University Faculty of Medicine, Farabi Hospital
    Trabzon, Trabzon 61080, Turkey (Türkiye)
08

References and documents

Publications

  • Tulgar S, Kapakli MS, Senturk O, Selvi O, Serifsoy TE, Ozer Z. Evaluation of ultrasound-guided erector spinae plane block for postoperative analgesia in laparoscopic cholecystectomy: A prospective, randomized, controlled clinical trial. J Clin Anesth. 2018 Sep;49:101-106. doi: 10.1016/j.jclinane.2018.06.019. Epub 2018 Jun 15. PubMed 29913392 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication (pain scores, analgesic consumption, incentive spirometry volumes, respiratory complications, and recovery outcomes) will be shared with researchers upon reasonable request to the corresponding author.

Supporting information: Study protocol

Time frame: Beginning with publication of the main results and ending 5 years after publication.

Access criteria: Data will be made available to researchers who submit a methodologically sound proposal to the corresponding author. Requests will be reviewed by the study investigators, and data will be shared in de-identified form for the purposes described in the approved proposal.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2024, 8 months.

Of 2,097 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 2,110 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Nov 6, 2023
Primary completionActual
Jul 17, 2024
CompletionActual
Aug 15, 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943975
Responsible party
Ali AKDOĞAN (Associate Professor, Department of Anesthesiology and Intensive Care, Karadeniz Technical University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 6, 2023
Primary completion
Jul 17, 2024
Completion
Aug 15, 2024
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion